All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On September 18, 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to ICT01, a humanized anti-butyrophilin 3A monoclonal antibody, in combination with azacitidine and venetoclax, for the treatment of patients aged ≥75 years with newly diagnosed acute myeloid leukemia (AML) unfit for induction chemotherapy.1 The decision is based on the encouraging results from the phase I dose-escalation portion of the EVICTION trial (NCT04243499).1,2
EVICTION is an ongoing open-label, dose-escalation, phase I/IIa trial evaluating ICT01 in patients with relapsed/refractory (R/R) hematological malignancies.1 Interim findings were presented at the European Society for Medical Oncology (ESMO) Congress 2023.3 Overall, 26 patients with R/R hematological malignancies received ICT01 monotherapy (AML; n = 24, follicular lymphoma; n = 1, diffuse large B-cell lymphoma; n = 1), at doses ranging from 200 μg to 75 mg every 21 days. The key findings were as follows:3
A dose-optimizing and efficacy-estimating portion has been initiated to evaluate two doses of ICT01 in combination with azacitidine and venetoclax in newly diagnosed patients with AML who are older or ineligible for standard chemotherapy. To date, 29 patients have been enrolled.1
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox